Search research articles
Contact Us
Filters
Showing results (121-130 of 132) with videos related to
Page
of 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2002
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients
V Dieras, P Bougnoux, T Petit, et al.
Leukemia & Lymphoma
|
January 1, 1996
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease
J Fleury, M Legros, P Colombat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2005
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
B P Coudert, L Arnould, L Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results
M Legros, J Dauplat, J Fleury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration
J L Misset, M di Palma, M Delgado, et al.
Breast Cancer Research and Treatment
|
November 27, 2004
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program
J Y Pierga, P Fumoleau, Y Brewer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 16, 2000
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience
J Bonneterre, M Spielman, J P Guastalla, et al.
British Journal of Cancer
|
May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
P Kerbrat, H Roché, J Bonneterre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti, B Perpoint, R Zidani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M J van den Bent, W Grisold, D Frappaz, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 132) with videos related to
Sort By:
Page
of 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2002
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients
V Dieras, P Bougnoux, T Petit, et al.
Leukemia & Lymphoma
|
January 1, 1996
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease
J Fleury, M Legros, P Colombat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2005
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
B P Coudert, L Arnould, L Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results
M Legros, J Dauplat, J Fleury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration
J L Misset, M di Palma, M Delgado, et al.
Breast Cancer Research and Treatment
|
November 27, 2004
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program
J Y Pierga, P Fumoleau, Y Brewer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 16, 2000
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience
J Bonneterre, M Spielman, J P Guastalla, et al.
British Journal of Cancer
|
May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
P Kerbrat, H Roché, J Bonneterre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti, B Perpoint, R Zidani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M J van den Bent, W Grisold, D Frappaz, et al.
Page
of 14